Walter Jeske, PhD

Thoracic and Cardiovascular Surgery

Pathology
Professor

Languages Spoken

English

Board Certification

American Nurses Credentialing Center
Anesthesiology
American Board of

Research

  • Analysis of Heparins Derived From Bovine Tissues and Comparison to Porcine Intestinal Heparins St Ange, K.; Onishi, A.; Fu, L.; Sun, X.; Lin, L.; Mori, D.; Zhang, F.; Dordick, J. S.; Fareed, J.; Hoppensteadt, D.; Jeske, W.; Linhardt, R. J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Anticoagulant and Antithrombotic Actions of AVE5026 an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin, Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sustained release of tissue factor following thrombosis of lower limb trauma Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
View All ResearchShow Less
  • The relationship between reticulated platelets intestinal alkaline phosphatase, and necrotizing enterocolitis, Kampanatkosol, R.; Thomson, T.; Habeeb, O.; Glynn, L.; Dechristopher, P. J.; Yong, S.; Jeske, W.; Maheshwari, A.; Muraskas, J., Journal of pediatric surgery
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S., American journal of cardiovascular disease
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Metabolic differences of current thienopyridine antiplatelet agents Fareed, J.; Jeske, W.; Thethi, I., Expert opinion on drug metabolism & toxicology
  • Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran rivaroxaban, and apixaban: potential clinical implication, Sadeghi, N.; Kahn, D.; Jeske, W.; Hoppensteadt, D.; Fareed, J., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • A comparison of the pharmacodynamic behavior of branded and biosimilar enoxaparin in primates. Jeske, W.; Litinas, E.; Khan, H.; Hoppensteadt, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Interactions of oversulfated chondroitin sulfate (OSCS) from different sources with unfractionated heparin. Gray, A.; Litinas, E.; Jeske, W.; Fareed, J.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins Walenga, J. M.; Jeske, W. P.; Escalante, V.; Hoppensteadt, D.; Fareed, J.; Bakhos, M., International angiology : a journal of the International Union of Angiology
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C., Thrombosis research
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J., Blood Coagulation & Fibrinolysis
  • Simple scoring system for early management of heparin-induced thrombocytopenia. Messmore, H. L.; Fabbrini, N.; Bird, M. L.; Choudhury, A. M.; Cerejo, M.; Prechel, M.; Jeske, W. P.; Siddiqui, A.; Thethi, I.; Wehrmacher, W. H.; Walenga, J. M., Clinical & Applied Thrombosis/Hemostasis
  • A consensus conference on complex biologics and low molecular weight heparin Kalodiki, E.; Fareed, J.; Tapson, W. F.; Hoppensteadt, D. A.; Carter, C. A.; Sussman, I.; Parker, S.; Harenberg, J.; Hull, R.; Rao, G.; Lovinger, D. F.; Reid, L. D.; Kakkar, A.; Talarico, L.; Ofosu, F. A.; Bussey, H. I.; Fanikos, J.; Groce, J. B.; Skinner, N.; Ahluwalia, M.; Iqbal, O.; Jackson, C. M.; Jeske, W. P.; Ramacciotti, E.; Van Thiel, D.; Wahi, R.; Walenga, J., International Angiology
  • Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist Mousa, S. A.; Jeske, W. P.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Comparative studies on the topical administration of mucopolysaccharide and heparin ointments in nonhuman primates. Hoppensteadt, D. A.; Neville, B.; Schultz, C.; Jeske, W.; Raake, W.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W., Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Biology
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M., Thrombosis research
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He, Z.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin. Viskov, C.; Bouley, E.; Hubert, P.; Martinez, C.; Herman, F.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. Akar, J. G.; Jeske, W.; Wilber, D. J., Journal of the American College of Cardiology
  • Are all low molecular weight heparins equivalent in the management of venous thromboembolism? Fareed, J.; Jeske, W.; Fareed, D.; Clark, M.; Wahi, R.; Adiguzel, C.; Hoppensteadt, D., Clinical & Applied Thrombosis/Hemostasis
  • Biological Profile of the Hyper/Oversulfated Chondroitin Sulfate Contaminant Isolated from Recalled Heparin Fareed, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Prechel, M.; Iqbal, O.; Adiguzel, C.; Clark, M.; Litinas, E.; cunanan, J.; Linhardt, R.; Harenberg, J., Seminars in thrombosis and hemostatis
  • Differentiating low-molecular-weight heparins based on chemical biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins, Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M., Clinical & Applied Thrombosis/Hemostasis
  • Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate. Clark, M.; Hoppensteadt, D.; Walenga, J. M.; Myers, L.; Cunanan, J.; Jeske, W.; Adiguzel, C.; Iqbal, O.; Fareed, J., International Angiology
  • Potency Adjusted Generic Versions of Argatroban can be Differentiated from Branded Argatroban in Thrombin Generation and Platelet Activation Assays Adiguzel, C.; Iqbal, O.; Cunanan, J.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • Rivaroxaban--an oral direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia., Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M., British journal of haematology
  • The anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors: experimental and clinical observations. Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Bick, R. L.; Fareed, J., Seminars in Thrombosis and Hemostasis
  • The future of anticoagulation Hoppensteadt, D. A.; Jeske, W.; Walenga, J. M.; Fareed, J., Seminars in Respiratory & Critical Care Medicine
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M., Current pharmaceutical design
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E., Clinical & Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Walenga, J. M.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J., Thrombosis research
  • Troponin I levels in patients with preeclampsia. Joyal, D.; Leya, F.; Koh, M.; Besinger, R.; Ramana, R.; Kahn, S.; Jeske, W.; Lewis, B.; Steen, L.; Mestril, R.; Arab, D., American Journal of Medicine
  • Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis. Maddineni, J.; Jeske, W. P.; Baltasar, F.; Cornelli, U.; Manoni, M.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L., Clinical & Applied Thrombosis/Hemostasis
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M., Future Cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M., Journal of Thrombosis & Haemostasis
  • Antiplatelet agents: current drugs and future trends Messmore, H. L., Jr; Jeske, W. P.; Wehrmacher, W.; Coyne, E.; Mobarhan, S.; Cho, L.; Leya, F. S.; Moran, J. F., Hematology - Oncology Clinics of North America
  • Comparative tissue factor pathway inhibitor release potential of heparins. Tobu, M.; Ma, Q.; Iqbal, O.; Schultz, C.; Jeske, W.; Hoppensteadt, D. A.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Development of generic low molecular weight heparins: a perspective Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Bick, R. L., Hematology - Oncology Clinics of North America
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents Walenga, J. M.; Jeske, W. P.; Fareed, J., Expert opinion on investigational drugs
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M., Current opinion in pulmonary medicine
  • A survey of venous thrombosis models Jeske, W. P.; Iqbal, O.; Fareed, J.; Kaiser, B., Methods in Molecular Medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Factor Xa inhibitors Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Methods in Molecular Medicine
  • Generic low-molecular-weight heparins: some practical considerations Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Wahi, R.; Bick, R. L., Seminars in Thrombosis & Hemostasis
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M., Methods in Molecular Medicine
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M., Seminars in Thrombosis & Hemostasis
  • Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates. Jeske, W.; Fareed, J., Seminars in Thrombosis & Hemostasis
  • Small-molecule direct antithrombins: argatroban Fareed, J.; Jeske, W. P., Bailliere's Best Practice in Clinical Haematology
  • Benefit-risk assessment of treatments for heparin-induced thrombocytopenia Messmore, H.; Jeske, W.; Wehrmacher, W.; Walenga, J. M., Drug Safety
  • Factor Xa inhibitors: today and beyond Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J., Current Opinion in Investigational Drugs
  • Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use. Tobu, M.; Iqbal, O.; Ma, Q.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Lewis, B.; Fareed, D.; Fareed, J., Clinical & Applied Thrombosis/Hemostasis
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T., Clinical pharmacokinetics
  • Pharmacodynamics and pharmacokinetics of C3 a heparin-derived oligosaccharide mixture, in non-human primates., Ma, Q.; Schultz, C.; Neville, B.; Jeske, W.; Hoppensteadt, D.; Cornelli, U.; Lee, J.; Lorens, S.; Hanin, I.; Fareed, J., Thrombosis research
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M., Perfusion